What is the price target for SLNO stock?
19 analysts have analysed SLNO and the average price target is 114.16 USD. This implies a price increase of 244.59% is expected in the next year compared to the current price of 33.13.
SOLENO THERAPEUTICS INC (SLNO) Forecast, Price Target & Analyst Ratings
NASDAQ:SLNO • US8342033094
Current stock price
33.13 USD
-0.49 (-1.46%)
Last:
Analyst forecast overview
View the latest analyst price targets, stock forecast, EPS estimates, revenue projections, revisions, full estimates, rating distribution and upgrades/downgrades for SOLENO THERAPEUTICS INC (SLNO).
Forecast Snapshot
Next Earnings Forecast
Earnings Estimate- Release Date
- May 5, 2026
- Period
- Q1 / 2026
- EPS Estimate
- $0.71
- Revenue Estimate
- 94.982M
Price Target Details & History
Consensus Price Target and Range
Mean target
$114.16
Upside
+ 244.59%
From current price of $33.13 to mean target of $114.16, Based on 19 analyst forecasts
Low
$60.60
Median
$116.28
High
$152.25
Price Target Revisions
1 Month
0.00%
3 Months
-1.42%
Price Target Summary
19 Wall Street analysts provided a forecast for the next 12 months for SLNO. The average price target is 114.16 USD. This implies a price increase of 244.59% is expected in the next year compared to the current price of 33.13.
The average price target has been revised downward by 1.42% in the past 3 months.
Analyst Ratings & History
Current Analyst Ratings
Analyst Ratings History
Analyst Ratings Consensus
ChartMill Buy Consensus
86.32%
SLNO was analyzed by 19 analysts. The buy percentage consensus is at 86. So analysts seem to be very confident about SLNO.
In the previous month the buy percentage consensus was at a similar level.
SLNO was analyzed by 19 analysts, which should be a sufficient number of analysts to have a meaningful average consensus rating.
Recent Upgrades & Downgrades
| Date | Firm | Action | From → To |
|---|---|---|---|
| 2026-03-04 | HC Wainwright & Co. | Maintains | Buy -> Buy |
| 2026-02-27 | Wells Fargo | Maintains | Overweight -> Overweight |
| 2026-02-26 | TD Cowen | Maintains | Buy -> Buy |
| 2026-01-20 | Wells Fargo | Maintains | Overweight -> Overweight |
| 2026-01-20 | HC Wainwright & Co. | Maintains | Buy -> Buy |
| 2025-11-18 | Wolfe Research | Initiate | Outperform |
| 2025-11-05 | Wells Fargo | Maintains | Overweight -> Overweight |
| 2025-08-27 | Guggenheim | Reiterate | Buy -> Buy |
| 2025-08-20 | Wells Fargo | Initiate | Overweight |
| 2025-08-18 | HC Wainwright & Co. | Maintains | Buy -> Buy |
| 2025-08-07 | Guggenheim | Maintains | Buy -> Buy |
| 2025-08-07 | Oppenheimer | Maintains | Outperform -> Outperform |
| 2025-07-11 | Baird | Maintains | Outperform -> Outperform |
| 2025-05-08 | Guggenheim | Maintains | Buy -> Buy |
| 2025-05-08 | Baird | Maintains | Outperform -> Outperform |
| 2025-04-24 | Piper Sandler | Maintains | Overweight -> Overweight |
| 2025-04-15 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2025-03-31 | HC Wainwright & Co. | Maintains | Buy -> Buy |
| 2025-03-28 | Guggenheim | Maintains | Buy -> Buy |
| 2025-03-28 | Stifel | Maintains | Buy -> Buy |
| 2025-03-27 | Laidlaw & Co. | Maintains | Buy -> Buy |
| 2025-03-27 | Cantor Fitzgerald | Maintains | Overweight -> Overweight |
| 2025-03-27 | Baird | Maintains | Outperform -> Outperform |
| 2025-03-05 | Stifel | Reiterate | Buy |
| 2025-03-03 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
Next Earnings Forecast Details
Next Earnings Details
- Release Date
- May 5, 2026
- Period
- Q1 / 2026
- EPS Estimate
- $0.71
- Revenue Estimate
- 94.982M
- Revenue Q2Q
- N/A
- EPS Q2Q
- 174.67%
- Number of Analysts
- 14
Next Earnings Revisions
Revenue (1 Month)
2.02%
Revenue (3 Months)
4.16%
EPS (1 Month)
-1.80%
EPS (3 Months)
1.53%
Next Earnings Summary
SLNO is expected to report earnings on 5/5/2026. The consensus EPS estimate for the next earnings is 0.71 USD and the consensus revenue estimate is 94.98M USD.
The next earnings revenue estimate has been revised upward by 4.16% in the past 3 months.
Full Analyst Estimates
Yearly Earnings Per Share (EPS), Revenue, EBIT, EBITDA and Operating Margin Analyst Estimates
| 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | ||
|---|---|---|---|---|---|---|---|
| Revenue YoY % growth | 190.405M | 486.37M 155.44% | 768.4M 57.99% | 1.075B 39.90% | |||
| EBITDA YoY % growth | -39.426M -75.70% | -185.684M -370.97% | 11.431M 106.16% | 247.56M 2,065.69% | 501.37M 102.52% | N/A | |
| EBIT YoY % growth | -41.384M -69.61% | -187.671M -353.49% | 9.414M 105.02% | 252.95M 2,586.96% | 491M 94.11% | N/A | |
| Operating Margin | N/A | N/A | 4.94% | 52.01% | 63.90% | N/A | |
| EPS YoY % growth | -2.97 10.54% | -4.26 -43.43% | 0.23 105.40% | 4.30 1,768.07% | 6.95 61.79% | 10.43 50.03% |
All data in USD
Quarterly Earnings Per Share (EPS), Revenue, EBIT and EBITDA Analyst Estimates
| Q1 / 26 | Q2 / 26 | Q3 / 26 | Q4 / 26 | |
|---|---|---|---|---|
| EPS Q2Q % growth | 0.71 174.67% | 0.99 1,204.06% | 1.18 150.56% | 1.42 77.86% |
| Revenue Q2Q % growth | 94.982M | 116.29M 256.10% | 127.17M 92.63% | 146.08M 59.25% |
| EBITDA Q2Q % growth | 43.35M 195.82% | 53.965M 1,077.80% | 76.89M 225.63% | N/A |
| EBIT Q2Q % growth | 34.568M 175.57% | 55.796M 955.11% | 67.83M 206.85% | 83.32M 110.53% |
All data in USD
Yearly Earnings Per Share (EPS) and Revenue Trends vs Historical Data
Long Term Forward Growth Forecast Summary
Long Term EPS Growth (CAGR)
EPS Next 3 Year
256.59%
EPS Next 5 Year
N/A
Long Term Revenue Growth (CAGR)
Revenue Next 3 Year
77.87%
Revenue Next 5 Year
N/A
Long Term EBIT Growth (CAGR)
EBIT Next 3 Year
N/A
EBIT Next 5 Year
N/A
SOLENO THERAPEUTICS INC / SLNO Forecast FAQ
Can you provide the upcoming earnings date for SOLENO THERAPEUTICS INC?
SOLENO THERAPEUTICS INC (SLNO) will report earnings on 2026-05-05.
What are the consensus estimates for SOLENO THERAPEUTICS INC (SLNO) next earnings?
The consensus EPS estimate for the next earnings of SOLENO THERAPEUTICS INC (SLNO) is 0.71 USD and the consensus revenue estimate is 94.98M USD.
How many analysts cover SOLENO THERAPEUTICS INC (SLNO) stock?
The number of analysts covering SOLENO THERAPEUTICS INC (SLNO) is 19.